LEVI-04
Asset
Soluble neurotrophin receptor fusion protein that binds neurotrophin-3 to reduce pain signaling.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- NTF3
- 8
- Indications
- 2
- Trials
- 1
- Developer
Named in the news on Nov 10, 2026. news.google.com
Indications
8Arthritis
Phase 2, Completed, NCT05618782, clinicaltrials.gov, Nov 12, 2026
Joint diseases
Phase 2, Completed, NCT05618782, clinicaltrials.gov, Nov 12, 2026
Knee osteoarthritis
Phase 2, Completed, NCT05618782, clinicaltrials.gov, Nov 12, 2026
5 more
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials2
- Evidence for its targets1
- Competitors7
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.